171261 InSolution™ AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem

171261
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₂₄H₂₅N₅O 866405-64-3

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
171261-1MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo.
      Catalogue Number171261
      Brand Family Calbiochem®
      SynonymsDorsomorphin, AMPK Inhibitor I, BMP Inhibitor I
      References
      ReferencesHao, J., et al. 2010. ACS Chem.Biol. 5, 245.
      Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
      Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
      Inoki, K., et al. 2003. Cell 115, 577.
      Fryer, L.G., 2002. FEBS Lett. 531, 189.
      Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.
      Product Information
      CAS number866405-64-3
      ATP CompetitiveY
      FormLiquid
      FormulationSupplied as a 10 mM (1 mg/250 µl) solution of AMPK Inhibitor, Compound C (Cat. No. 171260) in DMSO.
      Hill FormulaC₂₄H₂₅N₅O
      Chemical formulaC₂₄H₂₅N₅O
      Hygroscopic Hygroscopic
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetAMPK
      Primary Target IC<sub>50</sub>25.1, 148, and 234.6 nM, against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity, respectively
      Primary Target K<sub>i</sub>EC100 = 2.5 µM against BMP pathway-dependent dorsoventral development; EC50 = 5 µM against VEGF signaling-dependent intersomitic vessel formation in zebrafish embryo in vivo
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Irritant
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and freeze (-20°C). Once opened, stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      InSolution™ AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      InSolution™ AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem Certificates of Analysis

      TitleLot Number
      171261

      References

      Reference overview
      Hao, J., et al. 2010. ACS Chem.Biol. 5, 245.
      Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
      Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
      Inoki, K., et al. 2003. Cell 115, 577.
      Fryer, L.G., 2002. FEBS Lett. 531, 189.
      Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision22-March-2012 JSW
      SynonymsDorsomorphin, AMPK Inhibitor I, BMP Inhibitor I
      DescriptionA cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo.
      FormLiquid
      FormulationSupplied as a 10 mM (1 mg/250 µl) solution of AMPK Inhibitor, Compound C (Cat. No. 171260) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number866405-64-3
      Chemical formulaC₂₄H₂₅N₅O
      Structure formulaStructure formula
      Purity≥95% by HPLC
      Storage +2°C to +8°C
      Hygroscopic
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and freeze (-20°C). Once opened, stock solutions are stable for up to 3 months at -20°C.
      Toxicity Irritant
      ReferencesHao, J., et al. 2010. ACS Chem.Biol. 5, 245.
      Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
      Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
      Inoki, K., et al. 2003. Cell 115, 577.
      Fryer, L.G., 2002. FEBS Lett. 531, 189.
      Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.